Shah Capital pushes for Novavax sale, warns of proxy fight

Core Viewpoint - Shah Capital, the second-largest shareholder of Novavax, is urging the company's board to consider strategic changes, including a potential sale, and has indicated the possibility of initiating a proxy fight if no progress is made [1] Group 1 - Shah Capital is pressing for strategic changes at Novavax [1] - The potential sale of Novavax is being considered as part of the strategic changes [1] - A proxy fight may be launched by Shah Capital if the board does not take action [1]